Evidence map›Paper›PMID 40377867›Full record

ReviewDermatology and therapy2025

Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020-2023.

Julien Seneschal, Lgnasi Figueras Nart, Silvia Sabatino, Manny Papadimitropoulos, Srishti Dabral, Anastasia Lampropoulou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Julien SeneschalCHU de Bordeaux, Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Bordeaux, France.
Lgnasi Figueras NartDepartment of Dermatology, Institut d'Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge, University of Barcelona, Barcelona, Spain.
Silvia SabatinoEli Lilly and Company, Indianapolis, IN, USA.
Manny PapadimitropoulosEli Lilly Canada Inc, Exchange Tower, 130 King Street West, Suite 900, P.O. Box 73, Toronto, ON, M5X 1B1, Canada. papadimitropoulos_manny@lilly.com.
Srishti DabralEli Lilly and Company, Indianapolis, IN, USA.
Anastasia LampropoulouEli Lilly and Company, Indianapolis, IN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBaricitinib is an oral selective Janus kinase 1/2 inhibitor approved for the treatment of the immune-mediated inflammatory skin diseases atopic dermatitis (AD) and alopecia areata (AA). We report the findings of a systematic literature review of real-world outcomes with baricitinib in patients with AD or AA.

methodsDatabases, conference proceedings, and other sources were searched for publications covering July to November 2023 that provided real-world evidence in baricitinib-treated patients; extracted study variables included study population characteristics, interventions, and outcomes.

resultsIn total, 76 publications meeting inclusion criteria were identified, most of which were single-centre studies; 1134 unique patients with AD and 598 unique patients with AA were included. Studies in AD mostly focused on effectiveness outcomes, followed by treatment patterns, patient-reported outcomes, and safety. Most AA publications focused on effectiveness outcomes, followed by safety then treatment patterns.

conclusionOverall, baricitinib consistently improved the signs and symptoms of AD in patients receiving baricitinib in real-world settings, was effective for the treatment of AA in both adult and paediatric patients and was associated with improvements in patient-reported outcomes. The most common reasons for baricitinib discontinuation in AD were ineffectiveness and adverse events, although discontinuation rates due to adverse events were low. Patients initiating baricitinib for AD had often been treated previously with a biologic and were frequently receiving immunosuppressive and topical treatments before treatment initiation. Treatment discontinuation and prior treatment data were limited for studies in AA, but several studies reported concomitant minoxidil use in patients with AA treated with baricitinib. No new safety signals for baricitinib were observed in patients with AD or AA, and no serious adverse events were reported. In conclusion, real-world data on baricitinib in the treatment of AD and AA support the effectiveness and tolerability reported in clinical trials.

Indexed as

Alopecia areataAtopic dermatitisBaricitinibReal-world

Identifiers

PMID40377867
PMCPMC12126405

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.